



Merck & Company (MRK)

Updated October 27th, 2020 by Nathan Parsh

Key Metrics

Current Price:	\$78	5 Year CAGR Estimate:	10.5%	Market Cap:	\$199 billion
Fair Value Price:	\$89	5 Year Growth Estimate:	5.0%	Ex-Dividend Date:	12/14/2021 ¹
% Fair Value:	87%	5 Year Valuation Multiple Estimate:	2.8%	Dividend Payment Date:	1/8/2021 ²
Dividend Yield:	3.1%	5 Year Price Target	\$114	Years Of Dividend Growth:	9
Dividend Risk Score:	B	Retirement Suitability Score:	B	Last Dividend Increase:	10.9%

Overview & Current Events

Merck & Company is one of the largest healthcare companies in the world. Merck manufactures prescription medicines, vaccines, biologic therapies, and animal health products. Merck employs 69,000 people around the world and generates annual revenues of \$48+ billion. On 2/5/2020, Merck announced that it was spinning off its women's health, legacy brands and biosimilar products into a separate company. These businesses represent ~\$6.5 billion of revenues. The transaction should be completed in the first half of 2021.

Merck released third quarter earnings results on 10/27/2020. Revenue increased 1.2% to \$12.6 billion, topping estimates by \$340 million. Adjusted earnings-per-share increased 15.2% to \$1.74 and was \$0.31 better than expected. Currency exchange reduced revenue results by 1% for the third quarter.

Merck estimates that the COVID-19 pandemic reduced pharmaceutical revenue by \$475 million for the quarter and \$2.1 billion year-to-date. Still, Pharmaceutical revenues increased 2% to \$11.3 billion. *Keytruda*, which treats cancers such as melanoma that cannot be removed by surgery and non-small cell lung cancer, continues to grow as sales were up 21% to \$3.7 billion. U.S. sales were up 24%. *Keytruda* continues to receive new approvals for treatment in both the U.S. and Japan. Merck's HPV vaccine *Gardasil* had a sales decline of 10% due to weaker demand stemming from school closures in the U.S., though volumes remains robust in China and Europe. Sales for *Januvia/Janumet*, which treats diabetes and is Merck's second highest grossing product, improved 1% due to higher demand in international markets even as pricing pressure continues in the U.S. Animal Health sales improved 9% to \$1.2 billion due to higher demand in animal vaccines and parasitic control. Currency exchange reduced sales by 3% for this segment. Gross margins increased 450 basis points to 72.3% and SG&A expenses were lower by 5%. Merck has two COVID-19 vaccine trials in place as well as a novel antiviral candidate. Merck once again raised its guidance for the year. The company expects revenue in a range of \$47.6 billion to \$48.6 billion from \$47.2 billion to \$48.7 billion previously. Adjusted earnings-per-share are now expected in a range of \$5.91 to \$6.01, up from \$5.63 to \$5.78 previously. The midpoint for both ranges is above consensus estimates.

Growth on a Per-Share Basis

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2025
EPS	\$3.42	\$3.77	\$3.82	\$3.49	\$3.49	\$3.59	\$3.78	\$3.98	\$4.34	\$5.19	\$5.96	\$7.61
DPS	\$1.52	\$1.52	\$1.68	\$1.72	\$1.76	\$1.80	\$1.84	\$1.88	\$1.99	\$2.20	\$2.44	\$3.11
Shares³	3082	3041	3027	2928	2838	2781	2749	2697	2650	2603	2536	2450

Merck's earnings declined during the last recession and it took the company several years to return to growth. In fact, Merck has had earnings-per-share grow by about 4% per year over the past ten years. Merck has struggled to grow earnings as patents for drugs have expired, but *Keytruda* has shown very high rates of growth in recent reporting periods. *Keytruda* has patent protection in the U.S. until 2028, in the European Union until 2030, and in Japan until 2032. Due to this strength, as well as growth in other drugs, we estimate that Merck can grow earnings-per-share by at least 5% through 2025. After pausing its dividend from 2005 through 2011, Merck has increased its dividend at an average

¹ Estimated ex-dividend date

² Estimated payment date

³ In millions of shares

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Merck & Company (MRK)

Updated October 27th, 2020 by Nathan Parsh

rate of ~2% per year since. On 12/12/2019 the company increased its dividend to \$0.61/share quarterly. We expect dividends to grow at a 5% rate going forward.

Valuation Analysis

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Now	2025
Avg. P/E	10.5	9.1	10.8	13.3	16.4	15.8	15.2	15.6	16.2	17.5	13.1	15.0
Avg. Yld.	4.2%	4.4%	4.1%	3.7%	3.1%	3.2%	3.2%	3.0%	2.8%	2.4%	3.1%	2.7%

Shares of Merck have decreased \$2, or 2.5%, since our 8/1/2020 update. Based off of updated guidance for the current year, the stock has a forward price to earnings multiple of 13.1. Merck's long-term average price-to-earnings ratio is 12.6. Due to growth rates of key products, particularly *Keytruda*, we believe shares could trade with a price-to-earnings ratio of 15 by 2025. If shares were to revert to this target by 2025, then valuation would be a 2.8% tailwind to total returns over this time period.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2025
Payout	44%	40%	44%	49%	50%	50%	49%	47%	46%	42%	41%	41%

Many investors consider pharmaceutical companies "defensive" stocks because their products are in demand even in a protracted recession. The thinking goes that sick people will seek treatment for illnesses even in poor economic conditions, causing earnings to increase. While this is true for many names in this industry, Merck's earnings declined in 2009 and subsequent long road back to profitability that this is not necessarily true for every healthcare corporation. With that said, Merck's key competitive advantage is that it is seeing strong growth rates in key product areas. While generic competition is putting pressure on certain pharmaceuticals, we find *Keytruda*'s growth rate and peak sales expectations very appealing. Merck is also one of the largest pharmaceutical companies in the world, which gives the company size and scale. If needed, the company would likely have the ability to acquire other assets. Merck has also spent heavily (16%-19% of sales) on research and development over the past five years.

Final Thoughts & Recommendation

Merck & Company is now expected to offer a total annual return of 10.5% through 2025, up from our previous estimate of 9.1%. The company has managed to overcome the headwind of COVID-19 and show growth on both the top and bottom-line. *Keytruda* continues to see high double-digit growth rates as well as receive new approvals for use. *Keytruda* doesn't lose its patent protection until 2028 in the U.S., giving the product many years of growth. We have increased our 2025 price target \$5 to \$114 due to revised guidance. Merck continues to receive a buy recommendation from Sure Dividend due to projected returns.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Merck & Company (MRK)

Updated October 27th, 2020 by Nathan Parsh

Income Statement Metrics

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Revenue	45987	48047	47267	44033	42237	39498	39807	40122	42294	46840
Gross Profit	27591	31176	30821	27079	25469	24564	25777	27210	28785	32728
Gross Margin	60.0%	64.9%	65.2%	61.5%	60.3%	62.2%	64.8%	67.8%	68.1%	69.9%
SG&A Exp.	13125	13733	12776	11911	11606	10313	10017	10074	10102	10615
D&A Exp.	7381	7427	6978	6988	6691	6375	5471	4676	4519	3652
Operating Profit	3355	8976	9877	7665	6683	7547	5499	6797	8931	12241
Op. Margin	7.3%	18.7%	20.9%	17.4%	15.8%	19.1%	13.8%	16.9%	21.1%	26.1%
Net Profit	861	6272	6168	4404	11920	4442	3920	2394	6220	9843
Net Margin	1.9%	13.1%	13.0%	10.0%	28.2%	11.2%	9.8%	6.0%	14.7%	21.0%
Free Cash Flow	9144	10660	8068	10106	5672	11255	8762	4563	8307	9967
Income Tax	671	942	2440	1028	5349	942	718	4103	2508	1687

Balance Sheet Metrics

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Total Assets (\$B)	105781	105128	106132	105645	98167	101677	95377	87872	82637	84397
Cash & Equivalents	10900	13531	13451	15621	7441	8524	6515	6092	7965	9676
Acc. Receivable	7344	8261	7672	7184	6626	6484	7018	6873	7071	6778
Inventories	5868	6254	6535	6226	5571	4700	4866	5096	5440	5978
Goodwill & Int.	51834	46457	41217	36102	33378	40325	35467	32467	31357	33621
Total Liabilities	48976	48185	50669	53319	49376	56910	55069	53303	55755	58396
Accounts Payable	2308	2023	1753	2274	2625	2533	2807	3102	3318	3738
Long-Term Debt	17882	17515	20569	25060	21403	26412	24842	24410	25114	26346
Total Equity	54376	54517	53020	49765	48647	44676	40088	34336	26701	25907
D/E Ratio	0.33	0.32	0.39	0.50	0.44	0.59	0.62	0.71	0.94	1.02

Profitability & Per Share Metrics

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Return on Assets	0.8%	5.9%	5.8%	4.2%	11.7%	4.4%	4.0%	2.6%	7.3%	11.8%
Return on Equity	1.5%	11.5%	11.5%	8.6%	24.2%	9.5%	9.2%	6.4%	20.4%	37.4%
ROIC	1.1%	8.4%	8.2%	5.7%	16.2%	6.3%	5.8%	3.9%	11.2%	18.9%
Shares Out.	3082	3041	3027	2928	2838	2781	2749	2697	2650	2603
Revenue/Share	14.74	15.53	15.37	14.70	14.43	13.90	14.28	14.60	15.79	18.16
FCF/Share	2.93	3.45	2.62	3.37	1.94	3.96	3.14	1.66	3.10	3.86

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.